Login / Signup

Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.

Eric J MillerTracy L RoseBenjamin L MaughanMatthew I MilowskyMehmet Asim BilenBradley C CarthonXin GaoSuthee RapisuwonQianqian ZhaoMenggang YuNeeraj AgarwalMatthew D Galsky
Published in: Cancer (2024)
High dose CTLA-4 blockade in patients with PD-1/PD-L1-resistant metastatic urothelial cancer has modest activity and is associated with treatment-related toxicity similar to prior reports.
Keyphrases
  • papillary thyroid
  • high dose
  • squamous cell
  • small cell lung cancer
  • squamous cell carcinoma
  • low dose
  • oxidative stress
  • urinary tract
  • childhood cancer
  • stem cell transplantation
  • young adults
  • newly diagnosed